Inhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US Cohort Study
Thornburg C, van den Berg H, Chandler M, Malec L, Manuel M, O’Neill C, Recht M, Taggart E, Carpenter S, group A, Knoll C, Malec L, Wang M, Guerrera M, Tarango C, Sidonio R, Rodriguez N, Friedman K, Shapiro A, Yaish H, Carpenter S, Janbain M, Grabowski E, Pruthi R, Haley K, Thornburg C, Ahuja S, Simpson M, Reiss U, Lucas T, Balasa V, Wheeler A. Inhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US Cohort Study. Blood Vessels Thrombosis & Hemostasis 2025, 100082. DOI: 10.1016/j.bvth.2025.100082.Peer-Reviewed Original ResearchClotting factor concentratesSevere hemophilia AHemophilia AInhibitor developmentExposure daysCohort studyAssociated with inhibitor developmentLow-titer inhibitorsReduce inhibitor developmentHigh-titer inhibitorsCox proportional hazards modelsEvaluate risk factorsClinically significant inhibitorUS cohort studyProportional hazards modelCongenital hemophiliaUntreated patientsSevere HAClinical characteristicsPrevent bleedingNeutralizing antibodiesModerate haemophiliaNonsense variantFactor concentrationsRisk factors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply